The Senate

Community Affairs References Committee

Supply of chemotherapy drugs such as Docetaxel

© Commonwealth of Australia 2013

ISBN 978-1-74229-815-3

Secretariat

Dr Ian Holland (Committee Secretary)

Mr Gerry McInally (Principal Research Officer)

Mr Jarrod Baker (Senior Research Officer)

Ms Eloise Menzies (Research Officer)

Ms Carol Stewart (Administrative Officer)

PO Box 6100 Parliament House Canberra ACT 2600

Phone: 02 6277 3515 Fax: 02 6277 5829

E-mail: community.affairs.sen@aph.gov.au

Internet: www.aph.gov.au/senate/committee/senate_ca

This document was produced by the Senate Community Affairs Committee Secretariat and printed by the Senate Printing Unit, Parliament House, Canberra.

MEMBERSHIP OF THE COMMITTEE

43rd Parliament

Members

Senator Rachel Siewert, Chair

Senator Claire Moore, Deputy Chair

Senator Ronald Boswell

Senator Sue Boyce

Senator Carol Brown (to 25 February 2013)

Senator Dean Smith

Western Australia, AG

Queensland, ALP

Tasmania, ALP

Western Australia, LP

Tasmania, ALP

Participating members for this inquiry

Senator Concetta Fierravanti-Wells

Senator Nick Xenophon

New South Wales, LP

South Australia, IND

TABLE OF CONTENTS

MEMBERSHIP OF THE COMMITTEE	iii
LIST OF RECOMMENDATIONS	vii
Chapter 1	
Introduction	1
Terms of Reference	1
Conduct of the Inquiry	1
Structure of the report	1
Chapter 2	
Background to Inquiry	3
Introduction	3
Operation of the PBS	3
The Fifth Community Pharmacy Agreement	4
Price Disclosure	5
Chemotherapy Drugs in the PBS	5
Chapter 3	
Chemotherapy funding	7
Concerns raised by Private Providers	7
Negotiations concerning chemotherapy funding	10
The 5th Community Pharmacy Agreement Negotiations	11
Links between PBS Sustainability Measures	12
Correspondence between the Department and the Pharmacy Guild	15
Committee View	17

Coalition Senators' Additional comments

	A further delay on delivering funding certainty	.22
	Appropriateness of price disclosure	.22
	Poor understanding of significance of cross subsidisation in delivery of private chemotherapy services	.23
	Impact on access to cancer treatment for Australians living in regional areas	.24
	Abuse of good faith	.25
	The appropriateness of advocacy by providers and other health professionals	.26
	In Summary	.26
Ado	litional comments by Senator Nick Xenophon	
	Impact on patients	.27
	Funding arrangements for chemotherapy drugs	.29
	Government consultation	.30
AP]	PENDIX 1	
S	ubmissions and Additional Information received by the Committee	.33
AP]	PENDIX 2	
P	ublic Hearings	.37